Y 08
Alternative Names: Anti-IL-1RAP monoclonal antibody - U mab Biopharma; Y-08Latest Information Update: 03 Apr 2026
At a glance
- Originator U-mab Biopharma
- Developer Shanghai Henlius Biotech; U-mab Biopharma
- Class Anti-inflammatories; Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Interleukin-1 receptor accessory protein inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Autoimmune disorders; Inflammation
- Research Cancer
Most Recent Events
- 03 Apr 2026 Early research in Cancer in China (Parenteral), prior to April 2026 (U-mab Biopharma pipeline, April 2026)
- 14 Jan 2026 Shanghai Henlius Biotech enters into an exclusive global license agreement with U-mab Biopharma for Autoimmune disorders and Inflammation
- 14 Jan 2026 U mab Biopharma has patent protection for Anti-IL-1RAP monoclonal antibody